View Future GrowthVitrolife 과거 순이익 실적과거 기준 점검 0/6Vitrolife 의 수입은 연평균 -49.2%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 15.2%의 비율로 증가해 왔습니다.핵심 정보-49.15%순이익 성장률-49.64%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률15.19%자기자본이익률-62.07%순이익률-147.17%다음 순이익 업데이트16 Jul 2026최근 과거 실적 업데이트공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026공시 • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.모든 업데이트 보기Recent updates공시 • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.공시 • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Sweden공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.공시 • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.공시 • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.공시 • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.공시 • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden공시 • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.공시 • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026공시 • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.공시 • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025공시 • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.공시 • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.공시 • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.공시 • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.공시 • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.공시 • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.공시 • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024공시 • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).공시 • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.공시 • Oct 27+ 2 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023매출 및 비용 세부 내역Vitrolife가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VTRL.Y 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 263,405-5,0111,33112431 Dec 253,440-5,0121,31811830 Sep 253,5074401,28411030 Jun 253,5414551,26211331 Mar 253,6104981,24311031 Dec 243,6095131,23211730 Sep 243,555-3,8051,18111730 Jun 243,535-3,7991,15011831 Mar 243,499-3,8361,11812631 Dec 233,512-3,8511,11712730 Sep 233,4624021,09212230 Jun 233,4123881,07612431 Mar 233,3364121,04813331 Dec 223,2343941,00214330 Sep 222,89335396115730 Jun 222,50134981115131 Mar 222,05430565613331 Dec 211,68134150311430 Sep 211,54941535310330 Jun 211,4643993339431 Mar 211,2913253089131 Dec 201,2462873119230 Sep 201,2732763249730 Jun 201,33129434210231 Mar 201,50237736510531 Dec 191,48038335110030 Sep 191,3913713428830 Jun 191,2973393188031 Mar 191,1993242937431 Dec 181,1513102847230 Sep 181,1022942787030 Jun 181,0642842767031 Mar 181,0662762766931 Dec 171,0462642706930 Sep 171,0262552667130 Jun 179912342627031 Mar 179132112546831 Dec 168561902506230 Sep 168041882355530 Jun 167711962315531 Mar 167471862235331 Dec 157221832205630 Sep 156601542135630 Jun 1560913719548양질의 수익: VTRL.Y 은(는) 현재 수익성이 없습니다.이익 마진 증가: VTRL.Y는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VTRL.Y은 수익성이 없으며 지난 5년 동안 손실이 연평균 49.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 VTRL.Y의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: VTRL.Y은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: VTRL.Y는 현재 수익성이 없으므로 자본 수익률이 음수(-62.07%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 20:59종가2026/05/19 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vitrolife AB (publ)는 12명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierKallum TitchmarshBofA Global ResearchKallum TitchmarshBofA Global Research9명의 분석가 더 보기
공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025
공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026
공시 • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.
공시 • May 07+ 1 more updateVitrolife AB (publ) Approves Dividend, Payable on 12 May 2026Vitrolife AB (publ) at its Annual General Meeting held on May 5, 2026, resolved to distribute a dividend of SEK 1.10 per share. The record date for the dividend is 7 May 2026. Payment is expected to be made on 12 May 2026.
공시 • Feb 03+ 2 more updatesVitrolife AB (publ), Annual General Meeting, May 05, 2026Vitrolife AB (publ), Annual General Meeting, May 05, 2026. Location: gothenburg Sweden
공시 • Oct 25+ 3 more updatesVitrolife AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Vitrolife AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Apr 29Vitrolife AB (Publ) Approves Dividend for the Financial Year 2024Vitrolife AB (publ) at its AGM held on April 29, 2025, approved dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
공시 • Apr 10Vitrolife AB (publ) Announces CFO ChangesVitrolife AB (publ) announced that Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration. Helena Wennerström will remain as acting CFO until Pär takes office.
공시 • Mar 31Vitrolife AB (Publ) Appoints Rickard Ericsson as Svp InnovationVitrolife AB (publ) announced that Rickard Ericsson, formerly SVP Consumables and SVP Sales & Marketing, has been appointed SVP Innovation, effective immediately. With over ten years at the company, Rickard brings a deep understanding of the reproductive health market. In this new role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management, and Market Access. The Executive Management Team (EMT) now consists of: CEO: Bronwyn Brophy O'Connor Acting CFO: Helena Wennerström, COO: Ermanno Sironi, SVP Innovation: Rickard Ericsson, SVP Sales & Marketing: Olivia Natens, CHRO: Jessica Jonasson.
공시 • Feb 21The Vitrolife Group Appoints Ermanno Sironi as Chief Operating OfficerThe Vitrolife Group appointed Ermanno Sironi as Chief Operating Officer effective immediately. The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity. Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.
공시 • Jan 31Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025Vitrolife AB (publ), Annual General Meeting, Apr 29, 2025. Location: gothenburg, Sweden
공시 • Jan 30Vitrolife AB (Publ) Proposes DividendThe Board of Vitrolife AB (publ) proposed to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.
공시 • Dec 03Vitrolife AB (Publ) Announces Chief Financial Officer ChangesVitrolife AB (publ) announced that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.
공시 • Nov 16Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025Vitrolife AB (publ) announced that they will report fiscal year 2024 final results on Mar 27, 2025
공시 • Oct 27Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026Vitrolife AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026
공시 • Oct 04Vitrolife AB (Publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Patricia Hedelius, appointed by AMF Fonder & Pension; Jón Sigurdsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.
공시 • Jul 24+ 1 more updateVitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025Vitrolife AB (publ) announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • May 23Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.Vitrolife AB (publ) (OM:VITR) completed the acquisition of Stb Zorg B.V. on May 22, 2024. In 2023, Stb Zorg B.V. had revenues of €1.5 million.
공시 • May 03Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million on May 2, 2024. The initial purchase price, on a net debt free basis is €9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of €8.4 million. eFertility will be reported under the Technologies business area. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group´s cash.
공시 • Apr 27Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023Vitrolife AB (publ) at the Annual General Meeting held on 25 April 2024, approved dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day.
공시 • Feb 02+ 1 more updateVitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024Vitrolife AB (publ) announced that they will report fiscal year 2023 final results on Mar 27, 2024
공시 • Jan 24Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023Vitrolife AB (publ) reported non-cash impairment for the fourth quarter of 2023. Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021.
공시 • Oct 06Vitrolife AB (publ) Announces Election Committee AppointmentsVitrolife AB (publ) announced the following people have been appointed as members of the election committee for the Annual General Meeting in 2024: Niels Jacobsen, appointed by William Demant Invest A/S; Patrik Tigerschiöld, appointed by Bure Equity AB; Caroline Sjösten, appointed by Swedbank Robur Fonder AB; and Jón Sigurdsson, Chairman of the Board.
공시 • Aug 24Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice PresidentVitrolife AB (publ) announced that Maria Forss, has resigned from her position as SVP Consumables business area in the company as she will assume the role of CEO BICO Group AB. Maria has been employed within the company since 2012 and has been leading the Consumables business area since 2017.
공시 • Aug 01Vitrolife AB Announces Board ChangesVitrolife AB (publ) announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from August 1, 2023, when Bronwyn Brophy assumes the position as CEO. The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today. After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.
공시 • Jul 14+ 4 more updatesVitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vitrolife AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
공시 • Feb 02+ 1 more updateVitrolife AB (publ) Proposes Dividend for 2022Vitrolife AB (publ) proposed a dividend of SEK 0.85 per share for 2022 compared to SEK 0.80 per share a year ago, corresponding to SEK 115 million (SEK 108 million a year ago).
공시 • Feb 01Vitrolife AB (publ) Announces Executive ChangesVitrolife AB (publ) appointed Bronwyn Brophy as new CEO. Bronwyn Brophy has an impressive track record as a leader of global Life science and Medtech businesses. The Board of directors of the company find Bronwyn Brophy to be an exceptional candidate to effectuate Vitrolife's strategy to reach the company's full potential and thereby create increased shareholder value. Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The last years within Thermo Fischer Bronwyn Brophy was heading the Immunodiagnostics Division globally and before that served as President of the EMEA region. Bronwyn Brophy will join the company at the latest on 1 August 2023. As notified 12 September 2022, Thomas Axelsson will leave his position as CEO. This is expected to occur 31 March 2023. At that time Jón Sigurdsson, Chairman of the board, will assume the position as interim CEO until Bronwyn Brophy starts her appointment. Consequently, the board of directors has appointed the current board member Henrik Blomquist as chairman of the board until the annual general meeting 27 April 2023.
공시 • Oct 27+ 2 more updatesVitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023Vitrolife AB (publ) announced that they will report first half, 2023 results on Jul 14, 2023